March 20, 2026

Zevra Therapeutics, Inc. (ZVRA)

⚠️ No article content returned.

..

MeiraGTx Holdings plc (MGTX) Stock Analysis: Unveiling a 263.95% Potential Upside in the Burgeoning Gene Therapy Space

Investors looking to capitalize on the growing field of gene therapy may find compelling reasons to consider MeiraGTx Holdings plc (NASDAQ: MGTX). As a clinical-stage genetic medicines company, MeiraGTx is..

Butterfly Network, Inc. (BFLY) Stock Analysis: 40% Potential Upside with Cutting-Edge Medical Devices

For investors keen on the healthcare sector, Butterfly Network, Inc. (NASDAQ: BFLY) offers an intriguing opportunity with notable potential upside. This medical device company is at the forefront of ultrasound..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Biotechnology Innovator with Over 100% Upside Potential

KalVista Pharmaceuticals, Inc. (KALV) is making waves in the biotechnology sector with a robust pipeline aimed at addressing unmet medical needs in hereditary angioedema (HAE). Headquartered in Framingham, Massachusetts, this..

Intellia Therapeutics (NTLA) Stock Analysis: Exploring Nearly 92% Upside Potential in Biotech

Intellia Therapeutics, Inc. (NASDAQ: NTLA), a prominent player in the biotechnology sector, is gaining attention for its ambitious foray into gene editing treatments. With the current stock price at $13.15..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a 423% Potential Upside in the Biotech Sector

Anavex Life Sciences Corp. (NASDAQ: AVXL), a New York-based biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to treating neurological disorders. With a market capitalization..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating Potential Challenges with a Promising Revenue Growth

InnovAge Holding Corp. (NASDAQ: INNV), a company firmly rooted in the healthcare sector, operates within the medical care facilities industry in the United States. With a market capitalization of $1.13..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges with 25% Upside Potential

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a name that resonates with potential amidst the biotechnology sector, a field known for its innovative disruptions and transformative impact. While the company’s..

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Growth Potential and Challenges in the Cannabis Sector

As the cannabis industry continues to evolve, Cronos Group Inc. (NASDAQ: CRON) stands out as a key player, leveraging its presence across Canada, Israel, and other international markets. With a..

Auna SA (AUNA) Stock Analysis: Potential 24% Upside in the Healthcare Sector

Auna SA (AUNA), a Luxembourg-based healthcare provider, is garnering attention from investors due to its robust potential upside. With a market cap of $428.54 million, Auna offers an intriguing investment..

Xencor, Inc. (XNCR) Stock Analysis: A Biotech Gem with 137.90% Potential Upside

Xencor, Inc. (NASDAQ: XNCR) is capturing the attention of investors seeking opportunities within the healthcare sector, particularly in the biotechnology industry. With a market capitalization of $888.86 million, Xencor is..

Sonida Senior Living, Inc. (SNDA): Performance Highlights Amidst Navigating Challenges in the Healthcare Sector

Sonida Senior Living, Inc. (SNDA) stands as a significant player in the United States’ senior housing sector, offering a range of specialized services from independent and assisted living to memory..

Eton Pharmaceuticals, Inc. (ETON) Stock Report: Exploring a Promising 49.25% Potential Upside

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a burgeoning player in the healthcare sector focusing on rare diseases, is capturing investor attention with its impressive growth trajectory and substantial upside potential. With..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech Gem with Over 100% Upside Potential

Investors with an eye on the healthcare sector, particularly in biotechnology, may want to pay close attention to Trevi Therapeutics, Inc. (NASDAQ: TRVI). This promising clinical-stage biopharmaceutical company, headquartered in..

Oculis Holding AG (OCS) Stock Analysis: Unveiling an 86.86% Potential Upside in the Biotech Sector

For investors with an eye on the healthcare sector, Oculis Holding AG (OCS) presents a compelling opportunity, particularly given its position within the burgeoning biotechnology industry. Headquartered in Zug, Switzerland,..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Uncovering an 88% Potential Upside in Molecular Diagnostics

Castle Biosciences, Inc. (NASDAQ: CSTL), a prominent player in the molecular diagnostics field, is capturing investor interest with its innovative diagnostic solutions and significant potential upside. As a specialized healthcare..

REGENXBIO Inc. (RGNX) Stock Analysis: A Biotech Gem with 232.75% Upside Potential

Navigating the dynamic landscape of biotechnology, REGENXBIO Inc. (NASDAQ: RGNX) stands out as a clinical-stage company with a promising gene therapy portfolio. With a market capitalization of $431.48 million, this..

Community Health Systems, Inc. (CYH) Stock Analysis: Navigating the Healthcare Sector with a 20% Potential Upside

Community Health Systems, Inc. (NYSE: CYH) presents an intriguing case for investors interested in the healthcare sector, especially those eyeing potential gains of up to 20% based on the current..

OrthoPediatrics Corp. (KIDS) Stock Analysis: A Look at Its 50% Potential Upside

OrthoPediatrics Corp. (NASDAQ: KIDS), a prominent player in the medical devices industry with a focus on pediatric orthopedic solutions, has recently garnered significant attention from investors. The company’s specialized portfolio,..

Evolus, Inc. (EOLS) Stock Analysis: Unpacking a Potential 201.78% Upside for Investors

Evolus, Inc. (NASDAQ: EOLS), a key player in the healthcare sector, particularly in the specialty and generic drug manufacturing industry, presents a compelling case for investors eyeing significant upside potential...

Search

Funds

March 20, 2026

Search

Funds

March 20, 2026

FTSE 100

Funds